News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Interim Financial Report For Q1 2014 For The BioPorto


5/6/2014 9:21:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Summary of Q1 2014

Strategic development

* Bioporto has signed an agreement with Abbott for cross-licenses to both parties' respective IP rights within NGAL.
* BioPorto and Phadia has reached a settlement in the case before the Supreme Court regarding the invalidation of Phadia’s patent, which specifies the use of HNL (another designation for NGAL) as a diagnostic marker for human diseases. Along with the settlement, BioPorto receives a license for Phadia’s patents regarding NGAL worldwide.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES